32326199|t|Preclinical Targeted alpha- and beta--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
32326199|a|HER2-targeted therapies have drastically improved the outcome for breast cancer patients. However, when metastasis to the brain is involved, current strategies fail to hold up to the same promise. Camelid single-domain antibody-fragments (sdAbs) have been demonstrated to possess favorable properties for detecting and treating cancerous lesions in vivo using different radiolabeling methods. Here we evaluate the anti-HER2 sdAb 2Rs15d, coupled to diagnostic gamma- and therapeutic alpha- and beta--emitting radionuclides for the detection and treatment of HER2pos brain lesions in a preclinical setting. 2Rs15d was radiolabeled with 111In, 225Ac and 131I using DTPA- and DOTA-based bifunctional chelators and Sn-precursor of SGMIB respectively and evaluated in orthotopic tumor-bearing athymic nude mice. Therapeutic efficacy as well as systemic toxicity were determined for 131I- and 225Ac-labeled sdAbs and compared to anti-HER2 monoclonal antibody (mAb) trastuzumab in two different HER2pos tumor models. Radiolabeled 2Rs15d showed high and specific tumor uptake in both HER2pos SK-OV-3-Luc-IP1 and HER2pos MDA-MB-231Br brain lesions, whereas radiolabeled trastuzumab was unable to accumulate in intracranial SK-OV-3-Luc-IP1 tumors. Administration of [131I]-2Rs15d and [225Ac]-2Rs15d alone and in combination with trastuzumab showed a significant increase in median survival in 2 tumor models that remained largely unresponsive to trastuzumab treatment alone. Histopathological analysis revealed no significant early toxicity. Radiolabeled sdAbs prove to be promising vehicles for molecular imaging and targeted radionuclide therapy of metastatic lesions in the brain. These data demonstrate the potential of radiolabeled sdAbs as a valuable add-on treatment option for patients with difficult-to-treat HER2pos metastatic cancer.
32326199	62	66	HER2	Gene	2064
32326199	76	92	Brain Metastasis	Disease	MESH:D009362
32326199	133	137	HER2	Gene	2064
32326199	199	212	breast cancer	Disease	MESH:D001943
32326199	213	221	patients	Species	9606
32326199	237	247	metastasis	Disease	MESH:D009362
32326199	461	478	cancerous lesions	Disease	MESH:D009369
32326199	552	556	HER2	Gene	2064
32326199	562	568	2Rs15d	Chemical	-
32326199	698	711	brain lesions	Disease	MESH:D001927
32326199	738	744	2Rs15d	Chemical	-
32326199	767	772	111In	Chemical	MESH:C000615551
32326199	774	779	225Ac	Chemical	MESH:C000615155
32326199	784	788	131I	Chemical	MESH:C000614965
32326199	795	799	DTPA	Chemical	MESH:D004369
32326199	805	809	DOTA	Chemical	MESH:C071349
32326199	843	845	Sn	Chemical	MESH:D014001
32326199	859	864	SGMIB	Chemical	MESH:C438937
32326199	906	911	tumor	Disease	MESH:D009369
32326199	933	937	mice	Species	10090
32326199	980	988	toxicity	Disease	MESH:D064420
32326199	1009	1013	131I	Chemical	MESH:C000614965
32326199	1019	1024	225Ac	Chemical	MESH:C000615155
32326199	1060	1064	HER2	Gene	2064
32326199	1091	1102	trastuzumab	Chemical	MESH:D000068878
32326199	1120	1127	HER2pos	Disease	
32326199	1128	1133	tumor	Disease	MESH:D009369
32326199	1155	1161	2Rs15d	Chemical	-
32326199	1187	1192	tumor	Disease	MESH:D009369
32326199	1216	1227	SK-OV-3-Luc	CellLine	CVCL:4Y20
32326199	1244	1256	MDA-MB-231Br	CellLine	CVCL:A0YY
32326199	1257	1270	brain lesions	Disease	MESH:D001927
32326199	1293	1304	trastuzumab	Chemical	MESH:D000068878
32326199	1346	1357	SK-OV-3-Luc	CellLine	CVCL:4Y20
32326199	1362	1368	tumors	Disease	MESH:D009369
32326199	1389	1393	131I	Chemical	MESH:C000614965
32326199	1394	1401	-2Rs15d	Chemical	-
32326199	1406	1420	[225Ac]-2Rs15d	Chemical	-
32326199	1451	1462	trastuzumab	Chemical	MESH:D000068878
32326199	1517	1522	tumor	Disease	MESH:D009369
32326199	1568	1579	trastuzumab	Chemical	MESH:D000068878
32326199	1654	1662	toxicity	Disease	MESH:D064420
32326199	1773	1783	metastatic	Disease	MESH:D000092182
32326199	1907	1915	patients	Species	9606
32326199	1948	1965	metastatic cancer	Disease	MESH:D009369
32326199	Negative_Correlation	MESH:D000068878	MESH:D009369
32326199	Association	MESH:D001943	2064
32326199	Cotreatment	MESH:C000614965	MESH:D000068878
32326199	Negative_Correlation	MESH:C000614965	MESH:D009369
32326199	Association	MESH:D009362	2064

